From the Journals

Low VWF levels or blood group O not linked to intracerebral hemorrhage risk


 

FROM THROMBOSIS RESEARCH

In contrast to findings of previous research, low levels of von Willebrand Factor (VWF) and blood group O were not associated with a first-ever intracerebral hemorrhage (ICH), according to a study published in Thrombosis Research.

The researchers compared 176 cases of ICH with 349 age- and sex-matched controls. The mean patient age was 57 years, and 50% were women. The median time from baseline blood sampling to the first ICH was 5.6 years, according to the study reported by Kristina Johansson of Umeå (Sweden) University and her colleagues.

Complicated picture

The level of VWF differed significantly among blood groups: In individuals with blood group O, the mean VWF level was 1.29 kIU/L; for blood group A, it was 1.52 kIU/L; for blood group AB, 1.59 kIU/L; and in blood group B, 1.76 kIU/L. However, there was no difference in VWF concentration between cases and controls.

The researchers found no association between blood group O and the risk of ICH, a finding previously seen in other studies. They did, however, find that, in the limited number of patients with blood group B there was an association with a lower risk of ICH, compared with blood group A (odds ratio, 0.47; 95% confidence interval, 0.23-0.95).

“To our knowledge this is the largest prospective study investigating the association between VWF, ABO blood group and ICH. We found no association between VWF or blood group O and risk of future ICH,” the researchers concluded.

The study was funded by public institutions in Sweden. The authors declared that they had no conflicts.

SOURCE: Johansson K et al. Thromb Res. 2020 Jul 5;195:77-80.

Recommended Reading

Global blood supply runs low
MDedge Internal Medicine
Updated international consensus recommendations on management of acute upper GI bleeding
MDedge Internal Medicine
Phase 2 studies show potential of FcRn blockade in primary ITP
MDedge Internal Medicine
Occult HCV infection is correlated to unfavorable genotypes in hemophilia patients
MDedge Internal Medicine
Fear drives activity changes in hemophilia patients
MDedge Internal Medicine
Gene therapy effective in hemophilia B patients with neutralizing antibodies
MDedge Internal Medicine
FDA approves recombinant treatment for hemophilia A or B with inhibitors
MDedge Internal Medicine
Pandemic strains blood supply for COVID-19 and noninfected patients
MDedge Internal Medicine
Subcutaneous hep A vaccination as effective as intramuscular for bleeding disorder patients
MDedge Internal Medicine
Large cohort study: Bevacizumab safe, effective for severe HHT bleeds
MDedge Internal Medicine